Pedro Ortega, MD
Internal Medicine · Winter Park, FLNPI 1740251891
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 29.1% of the total. Reporting peaked in 2020 at $851 and has fallen 67.0% since, to $281 in 2025.
Across 191 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$981
- GSK$367
- Novo Nordisk$287
- Amarin Pharma, Inc.$201
- Amgen$188
- AbbVie$169
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,353100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $981 |
| GSK | 21 | $367 |
| Novo Nordisk | 18 | $287 |
| Amarin Pharma, Inc. | 10 | $201 |
| Amgen | 11 | $188 |
| AbbVie(2 entities) | 9 | $169 |
| Exact Sciences | 9 | $151 |
| Abbott | 7 | $149 |
| Sanofi-aventis U.S. LLC | 7 | $123 |
| Astellas Pharma US Inc | 4 | $110 |
| Boehringer Ingelheim | 6 | $106 |
| Lilly USA, LLC | 4 | $64 |
| Pfizer | 3 | $61 |
| Bayer | 3 | $53 |
| Novartis | 3 | $49 |
| Johnson & Johnson | 3 | $48 |
| Renalytix AI, Inc. | 2 | $45 |
| Merck | 3 | $40 |
| Mannkind Corporation | 2 | $32 |
| Boston Scientific | 1 | $28 |
| Intra-sana Laboratories | 1 | $26 |
| Phadia US Inc. | 1 | $21 |
| Biogen | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Covidien LP | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$3,368 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 21 | $367 |
| Zolpidem Tartrate | 11 | $233 |
| Amlodipine Besylate | 17 | $197 |
| Levothyroxine Sodium | 21 | $190 |
| Pantoprazole Sodium | 17 | $159 |
| Lorazepam | 13 | $153 |
| Atorvastatin Calcium | 15 | $133 |
| Famotidine | 11 | $132 |
| Losartan Potassium | 15 | $111 |
| Clonazepam | 11 | $101 |
| Alprazolam | 13 | $91 |
| Tramadol Hcl | 16 | $82 |
| Montelukast Sodium | 11 | $82 |
| Metformin Hcl | 13 | $35 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Winter Park
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
- Quang NguyenOcala$434K
- Luis Correa LunaSanford$412K
- Michael OleksykFort Myers$365K
- Andrew KuykendallTampa$322K
- Howard FederoffCoconut Grove$302K
- Bianka EperjesiovaGainesville$260K
- Julio ConradoFort Myers$247K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.